RVU.WAR Ryvu Therapeutics SA
- Market cap
- PLN 412M
- P/E
- -
- P/B
- 14.85x
- ROE
- -181.2%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RVU.WAR undervalued?
Graham numberThe Graham number of Ryvu Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ryvu Therapeutics SA fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-181.2%), below 10%.
ROA 0/1
Return on assets (-28.2%) is below the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (9.2%) is above the industry median (2.6%).
Revenue Growth 2/2
Revenue grew 17.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (264.1%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (14.8x) is above the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Ryvu Therapeutics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kin…
Full company profileRyvu Therapeutics SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ryvu Therapeutics SA annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.1M | 87.8M | 77.2M | 42.6M | 15.4M | 11.2M | 38.8M | 46.9M | 78.0M | 62.3M | 57.9M |
| Gross Profit | 31.3M | 61.9M | 47.6M | -50.2M | 6.65M | -2.54M | 21.4M | 29.3M | 58.4M | -117M | 42.6M |
| Operating Income | -1.21M | 12.6M | -13.6M | -45.1M | -35.7M | -104M | -78.4M | -101M | -122M | -122M | -58.3M |
| EBITDA | 2.48M | 17.9M | -15.7M | -35.7M | -17.9M | -66.0M | -65.2M | -81.0M | -96.8M | -113M | -33.9M |
| Net Income | 2.72M | 6.41M | -106K | -36.0M | -31.7M | -79.1M | -83.8M | -92.1M | -111M | -101M | -51.4M |
| EPS | 0.20 | 0.47 | -0.01 | -2.25 | -1.89 | -4.31 | -4.57 | -4.02 | -4.82 | -4.38 | -2.36 |
| Balance Sheet | |||||||||||
| Total Assets | 89.1M | 104M | 256M | 183M | 296M | 229M | 475M | 403M | 379M | 224M | 183M |
| Total Liabilities | 33.4M | 39.6M | 60.8M | 63.1M | 71.9M | 59.4M | 132M | 144M | 235M | 154M | 154M |
| Shareholders' Equity | 55.4M | 62.3M | 192M | 120M | 224M | 161M | 343M | 260M | 144M | 53.8M | 28.4M |
| Cash & Short-term Investments | 29.1M | 36.1M | 110M | 72.1M | 161M | 88.2M | 102M | 234M | 225M | 108M | 74.7M |
| Total Debt | 9.62M | 7.99M | 13.5M | 9.22M | 7.41M | 5.07M | 2.77M | 906K | 75.5M | 71.7M | 74.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.28M | 11.0M | -36.4M | -17.4M | -10.6M | -57.9M | 21.3M | -84.6M | -129M | -110M | -64.9M |
| Capital Expenditure | 21.2M | 21.6M | 23.4M | 24.0M | 34.2M | 12.0M | 9.29M | 8.58M | 5.90M | 7.47M | 1.80M |
| Free Cash Flow | -27.5M | -10.6M | -59.9M | -41.4M | -44.8M | -69.8M | 12.0M | -88.1M | -135M | -118M | -66.7M |
| Ratios | |||||||||||
| ROE | 4.9% | 10.3% | -0.1% | -30.1% | -14.2% | -49.0% | -24.4% | -35.5% | -77.4% | -188.0% | -181.2% |
| ROA | 3.1% | 6.2% | 0.0% | -19.7% | -10.7% | -34.6% | -17.6% | -22.8% | -29.4% | -45.1% | -28.2% |
| Net Profit Margin | 5.7% | 7.3% | -0.1% | -84.6% | -205.6% | -706.9% | -215.9% | -196.6% | -142.9% | -162.6% | -88.8% |
| Debt to Equity | 0.17x | 0.13x | 0.07x | 0.08x | 0.03x | 0.03x | 0.01x | 0.00x | 0.52x | 1.33x | 2.64x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ryvu Therapeutics SA dividends
Ryvu Therapeutics SA has not paid dividends in the last 9 fiscal years.
Who owns Ryvu Therapeutics SA
- Insiders 35.02%
- Institutions 24.28%
- Public & others 40.70%
- Shares outstanding 23.1M
- Free float 16.0M
Ryvu Therapeutics SA company profile
- Company name
- Ryvu Therapeutics SA
- Ticker
- RVU.WAR
- ISIN
- PLSELVT00013
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 228
- Fiscal year end
- December
- Address
- Leona Henryka Sternbacha 2, Kraków, Poland, 30-394
- Phone
- 48 12 314 0200
- Website
- ryvu.com
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Ryvu Therapeutics SA management
7- Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.Founder, President of the Management Board & CEO
- Dr. Krzysztof Daniel Brzozka M.B.A., Ph.D.Executive VP, Chief Scientific Officer & VP of the Management Board
- Dr. Kamil Sitarz M.B.A., Ph.D.COO & Member of the Management Board
- Mr. Vatnak Vat-Ho M.B.A.Chief Business Officer & Member of Management Board
- Dr. Hendrik Nogai M.D.Chief Medical Officer & Member of Management Board
- Ms. Justyna ZoltekMember of the Management Board
- Ms. Paulina WolaninHuman Resources Manager